Top

Osteoporosis International

Published in:

Open Access 01-10-2011 | Review

The impact of pharmacist interventions on osteoporosis management: a systematic review

Authors: M. N. Elias, A. M. Burden, S. M. Cadarette

Published in: Osteoporosis International | Issue 10/2011

Abstract

Summary

We completed a systematic review of the literature to examine the impact of pharmacist interventions in improving osteoporosis management. Results from randomized controlled trials suggest that pharmacist interventions may improve bone mineral density testing and calcium intake among patients at high risk for osteoporosis.

Introduction

Pharmacists play a key role in many healthcare systems by helping patients manage chronic diseases. We completed a systematic review of the literature to identify randomized controlled trials (RCTs) that have examined the impact of pharmacy interventions in narrowing two gaps in osteoporosis management: identifying at-risk individuals and improving adherence to therapy.

Methods

We searched the electronic databases of EMBASE, HealthStar, International Pharmaceutical Abstracts, MEDLINE, and PubMed from database development to April 2010, examined grey literature, and completed manual searches of reference lists to identify English-language research that examined osteoporosis management interventions within pharmacy practice. Results from RCTs were abstracted and assessed for bias.

Results

We identified 25 studies that examined pharmacist interventions in osteoporosis management: 16 cohort, 5 cross-sectional, 1 historical/ecological control, and 3 RCTs. RCT interventions included osteoporosis educational and counseling programs, screening by pharmacists based on risk factor assessment or bone mineral density testing, and physician contact or recommendations for patients to follow-up with a general practitioner. Results from the three RCTs suggest that pharmacist interventions may improve bone mineral density testing (targeted screening) and calcium intake among patients at high risk for osteoporosis. However, two of the three RCTs had high risk of bias, and no study examined the impact of pharmacist intervention on osteoporosis treatment adherence.

Conclusions

Data support the potential role for pharmacists to help reduce gaps in osteoporosis management through improved identification of high-risk patients. More research is needed to examine pharmacist interventions on osteoporosis treatment adherence.

Available only for authorised users

Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–778PubMedCrossRef

Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031PubMedCrossRef

Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501PubMedCrossRef

Little EA, Eccles MP (2010) A systematic review of the effectiveness of interventions to improve post-fracture investigation and management of patients at risk of osteoporosis. Implement Sci 5:80–97PubMedCrossRef

Lai P, Chua SS, Chan SP (2010) A systematic review of interventions by healthcare professionals on community-dwelling postmenopausal women with osteoporosis. Osteoporos Int 21:1637–1656PubMedCrossRef

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 18:CD005326

Alberani V, De Castro PP, Mazza AM (1990) The use of grey literature in health sciences: a preliminary survey. Bull Med Libr Assoc 78:358–363PubMed

Charrois T, Durec T, Tsuyuki RT (2009) Systematic reviews of pharmacy practice research: methodologic issues in searching, evaluating, interpreting, and disseminating results. Ann Pharmacother 43:118–122PubMedCrossRef

Juni P, Altman DG, Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323:42–46PubMedCrossRef

10.

Vandenbroucke JP, von Elm E, Altman DG et al (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 147:W163–W194PubMed

11.

Taylor SJ, Crockett JA, McLeod LJ (2004) An integrated service, initiated by community pharmacists, for the prevention of osteoporosis. In Australian Government Department of Health and Ageing (ed)

12.

Cerulli J, Zeolla MM (2004) Impact and feasibility of a community pharmacy bone mineral density screening and education program. J Am Pharm Assoc (2003) 44:161–167CrossRef

13.

Elliott ME, Meek PD, Kanous NL et al (2002) Pharmacy-based bone mass measurement to assess osteoporosis risk. Ann Pharmacother 36:571–577PubMedCrossRef

14.

Goode JV, Swiger K, Bluml BM (2004) Regional osteoporosis screening, referral, and monitoring program in community pharmacies: findings from Project ImPACT: Osteoporosis. J Am Pharm Assoc (2003) 44:152–160CrossRef

15.

Hall LN, Shrader SP, Ragucci KR (2009) Evaluation of compliance with osteoporosis treatment guidelines after initiation of a pharmacist-run osteoporosis service at a family medicine clinic. Ann Pharmacother 43:1781–1786PubMedCrossRef

16.

Ho C, Cranney A, Campbell A (2006) Measuring the impact of pharmacist intervention: results of patient education about osteoporosis after fragility fracture. Can J Hosp Pharm 59:184–193

17.

Johnson JF, Koenigsfeld C, Hughell L, Parsa RA, Bravard S (2008) Bone health screening, education, and referral project in northwest Iowa: creating a model for community pharmacies. J Am Pharm Assoc (2003) 48:379–387CrossRef

18.

Law AV, Shapiro K (2005) Impact of a community pharmacist-directed clinic in improving screening and awareness of osteoporosis. J Eval Clin Pract 11:247–255PubMedCrossRef

19.

MacLaughlin EJ, MacLaughlin AA, Snella KA et al (2005) Osteoporosis screening and education in community pharmacies using a team approach. Pharmacotherapy 25:379–386PubMedCrossRef

20.

Nadrash TA, Plushner SL, Delate T (2008) Clinical pharmacists' role in improving osteoporosis treatment rates among elderly patients with untreated atraumatic fractures. Ann Pharmacother 42:334–340PubMedCrossRef

21.

Naunton M, Peterson GM, Jones G (2006) Pharmacist-provided quantitative ultrasound screening for rural women at risk of osteoporosis. Ann Pharmacother 40:38–44PubMed

22.

Newman ED, Hanus P (2001) Improved bone health behavior using community pharmacists as educators: the Geisinger health system community pharmacist osteoporosis education program. Dis Manag Health Outcomes 9:329–335CrossRef

23.

Riley K, Martin J, Wazny LD (2005) Impact of pharmacist intervention on osteoporosis treatment after fragility fracture: positive effect of pharmacist information program shown in pilot study. Can Pharm J 138:37–43

24.

Siow JY, Lai PS, Chua SS, Chan SP (2009) The impact of pharmacist intervention on the use of activated vitamin D in a tertiary referral hospital in Malaysia. Int J Pharm Pract 17:305–311PubMedCrossRef

25.

Stroup JS, Rivers SM, Abu-Baker AM et al (2007) Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic. Pharmacotherapy 27:779–788PubMedCrossRef

26.

Summers KM, Brock TP (2005) Impact of pharmacist-led community bone mineral density screenings. Ann Pharmacother 39:243–248PubMedCrossRef

27.

Peters S, Singla D, Raney E (2006) Impact of pharmacist-provided osteoporosis education and screening in the workplace. J Am Pharm Assoc (2003) 46:216–218CrossRef

28.

Chaiyakunapruk N, Laowakul A, Karnchanarat S, Pikulthong N, Ongphiphadhanakul B (2006) Community pharmacy-based implementation and evaluation of an osteoporosis self-assessment tool for Asians. J Am Pharm Assoc (2003) 46:391–396CrossRef

29.

Gloth FM, Simonson W (2008) Osteoporosis is underdiagnosed in skilled nursing facilities: a large-scale heel BMD screening study. J Am Med Dir Assoc 9:190–193PubMedCrossRef

30.

Liu Y, Nevins JC, Carruthers KM et al (2007) Osteoporosis risk screening for women in a community pharmacy. J Am Pharm Assoc (2003) 47:521–526CrossRef

31.

Wilcock M, MacMahon D, Woolf A (2005) Use of medicines that influence falls or fractures in a residential home setting. Pharm World Sci 27:220–222PubMedCrossRef

32.

Lata PF, Binkley NC, Elliott ME (2002) Acceptability of pharmacy-based bone density measurement by women and primary healthcare providers. Menopause 9:449–455PubMedCrossRef

33.

Naunton M, Peterson GM, Jones G, Griffin GM, Bleasel MD (2004) Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol 31:550–556PubMed

34.

Crockett JA, Taylor SJ, McLeod LJ (2008) Patient responses to an integrated service, initiated by community pharmacists, for the prevention of osteoporosis. Int J Pharm Pract 16:65–72CrossRef

35.

McDonough RP, Doucette WR, Kumbera P, Klepser DG (2005) An evaluation of managing and educating patients on the risk of glucocorticoid-induced osteoporosis. Value Health 8:24–31PubMedCrossRef

36.

Yuksel N, Majumdar SR, Biggs C, Tsuyuki RT (2010) Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial. Osteoporos Int 21:391–398PubMedCrossRef

37.

Hepler CD, Strand LM (1990) Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 47:533–543PubMed

38.

Jones EJ, Mackinnon NJ, Tsuyuki RT (2005) Pharmaceutical care in community pharmacies: practice and research in Canada. Ann Pharmacother 39:1527–1533PubMedCrossRef

39.

Machado M, Bajcar J, Guzzo GC, Einarson TR (2007) Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother 41:1569–1582PubMedCrossRef

40.

Machado M, Bajcar J, Guzzo GC, Einarson TR (2007) Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother 41:1770–1781PubMedCrossRef

41.

Machado M, Nassor N, Bajcar JM, Guzzo GC, Einarson TR (2008) Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother 42:1195–1207PubMedCrossRef

42.

Barr RJ, Stewart A, Torgerson DJ, Reid DM (2010) Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk. Osteoporos Int 21:561–568PubMedCrossRef

43.

Cook RB, Collins D, Tucker J, Zioupos P (2005) Comparison of questionnaire and quantitative ultrasound techniques as screening tools for DXA. Osteoporos Int 16:1565–1575PubMedCrossRef

44.

Fan E, Laupacis A, Pronovost PJ, Guyatt GH, Needham DM (2010) How to use an article about quality improvement. JAMA 304:2279–2287PubMedCrossRef

45.

Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377–384PubMedCrossRef

46.

Higgins J, Green S (eds) (2009) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. Available from www.cochrane-handbook.org

47.

Cadarette SM, Burden AM (2010) Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol 22:397–403PubMedCrossRef

48.

Gleeson T, Iversen MD, Avorn J et al (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20:2127–2134PubMedCrossRef

49.

Cadarette SM, Beaton DE, Gignac MAM et al (2007) Minimal error in self-report of having had DXA, but self-report of its results was poor. J Clin Epidemiol 60:1306–1311PubMedCrossRef

50.

Cadarette SM, Jaglal SB, Raman-Wilms L, Beaton DE, Paterson JM (2011) Osteoporosis quality indicators using healthcare utilization data. Osteoporos Int 22:1335–1342PubMedCrossRef

Title: The impact of pharmacist interventions on osteoporosis management: a systematic review
Authors: M. N. Elias
A. M. Burden
S. M. Cadarette
Publication date: 01-10-2011
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 10/2011
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-011-1661-7

At a glance: The STEP trials

Springer Medicine

The impact of pharmacist interventions on osteoporosis management: a systematic review

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2011

Intra-and inter-reader reliability of semi-automated quantitative morphometry measurements and vertebral fracture assessment using lateral scout views from computed tomography

Accounting for racial/ethnic variation in bone mineral content and density: the competing influences of socioeconomic factors, body composition, health and lifestyle, and circulating androgens and estrogens

Pubertal timing and body mass index gain from birth to maturity in relation with femoral neck BMD and distal tibia microstructure in healthy female subjects

Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)

Relationship between serum RANKL and RANKL in bone

Hip fractures in a city in Northern Norway over 15 years: time trends, seasonal variation and mortality